Welcome to our dedicated page for Clene SEC filings (Ticker: CLNNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Clene's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Clene's regulatory disclosures and financial reporting.
Clene Inc. director Jonathon Gay reported receiving a grant of stock options. The award covers 3,271 shares of Common Stock, granted on February 19, 2026 under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share. The options vest immediately upon grant, and Gay now directly holds 3,271 stock options following this acquisition.
Clene Inc. director Matthew Kiernan received a grant of stock options covering 2,755 shares of common stock. The options were granted on February 19, 2026 under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share and vest immediately upon grant.
Clene Inc. insider Symbiosis II LLC has filed a notice to sell 60,842 shares of CLNN common stock. The planned sale, through Merrill Lynch on Nasdaq around 01/29/2026, has an aggregate market value of $265,731, compared with 10,333,980 shares outstanding.
The shares were acquired on 06/20/2023 via an open-market purchase for cash. The filing also lists numerous prior open-market sales by Symbiosis II LLC from December 2025 through January 29, 2026, with gross proceeds disclosed for each trade. The seller represents it is not aware of undisclosed material adverse information about Clene.
Clene Inc.’s 10% owner Chidozie Ugwumba, through affiliated entity Symbiosis II, LLC, reported a series of indirect open‑market sales of Clene common stock. The LLC sold 15,284 shares at $4.32 on January 29, 5,686 shares at $4.13 on January 30, and 3,800 shares at $4.04 on February 2, 2026. Following the latest transaction, 555,559 shares of Clene common stock are reported as indirectly owned by Symbiosis II, LLC.
Clene Inc.’s 10% owner Ugwumba Chidozie reported a series of indirect share sales through Symbiosis II, LLC. On January 26, 2026, Symbiosis II, LLC sold 6,418 shares of Clene common stock at $5.02 per share. On January 27, 2026, it sold 4,139 shares at $5.08 per share. On January 28, 2026, it sold 8,717 shares at $4.91 per share. Following the latest transaction, Symbiosis II, LLC beneficially owned 580,329 Clene common shares indirectly attributed to the reporting person.
Clene Inc. 10% owner Ugwumba Chidozie reported indirect sales of Clene common stock through Symbiosis II, LLC. On January 22, 2026, Symbiosis II, LLC sold 12,665 shares of common stock at $5.32 per share, after which it held 605,159 shares beneficially. On January 23, 2026, it sold a further 5,556 shares at $5.27 per share, leaving 599,603 shares beneficially owned indirectly by the reporting person.
Clene Inc.'s Chief Financial Officer received a new stock option grant. On January 22, 2026, CFO Morgan R. Brown was granted a stock option covering 35,000 shares of Clene Inc. common stock under the company’s Amended 2020 Stock Plan. The option has an exercise price of $5.42 per share and is reported as held directly. According to the disclosure, the options vest immediately upon grant, meaning they are fully exercisable from the grant date, and following this transaction the reporting person beneficially owns 35,000 derivative securities tied to common stock.
Clene Inc.'s Chief Science Officer, Mark Mortenson, received a new stock option grant. On January 22, 2026, he was awarded options to purchase 75,000 shares of Clene Inc. common stock at an exercise price of $5.42 per share under the Clene Inc. Amended 2020 Stock Plan. The filing notes that these options vest immediately upon grant, meaning they are fully exercisable right away. Following this grant, Mortenson holds 75,000 derivative securities (stock options) directly.
Clene Inc. reported an insider equity award for President and CEO Robert Dee Etherington, who is also a director. On January 22, 2026, he received a stock option for 75,000 shares of common stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $5.42 per share. The footnote explains that these options vest immediately upon grant and are exercisable until January 21, 2036. Following this grant, Etherington directly holds 75,000 derivative securities in the form of these stock options.
Clene Inc. 10% owner Ugwumba Chidozie, through Symbiosis II, LLC, reported three open-market sales of Clene common stock. On January 16, 2026, Symbiosis II, LLC sold 7,923 shares at $5.13 per share. On January 20, 2026, it sold a further 12,432 shares at $4.80 per share, and on January 21, 2026, it sold 12,119 shares at $5.05 per share. After the last transaction, Symbiosis II, LLC indirectly held 617,824 shares of Clene common stock, reflecting the updated ownership position associated with the reporting person.